Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart, Tislelizumab, and Lenvatinib in Advanced TP53-Mutated Unresectable HCC
NCT07535840Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of genakumab in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate up to 24 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07535840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535840.